Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
Want to see ENLV full AI Analyst Report?
ENLV Stock Chart & Stats
$0.86
-$0.07(-5.60%)
At close: 4:00 PM EST
$0.86
-$0.07(-5.60%)
Day’s Range― - ―
52-Week Range$0.66 - $2.10
Previous CloseN/A
Volume59.48K
Average Volume (3M)182.02K
Market Cap
$210.91M
Enterprise Value$18.71M
Total Cash (Recent Filing)$5.87M
Total Debt (Recent Filing)$641.00K
Price to Earnings (P/E)<0.1
Beta0.58
Next Earnings
May 22, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)25.79
Shares Outstanding237,381,500
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-56.35
Enterprise Value/Ebitda-1.31
Forecast
1Y Price Target
$20.00Price Target Upside2225.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress - Phase 2b INDIND clearance for a randomized, double-blind Phase 2b in knee osteoarthritis advances Allocetra into a statistically powered late-stage trial for a large, aging-market indication. This materially de-risks clinical development path and supports a potential commercial pathway if endpoints are met.
Low Financial LeverageNear-zero debt reduces default and refinancing risk, giving management flexibility to fund R&D, execute strategic financings, or monetize treasury assets without near-term interest burden. Low leverage strengthens balance-sheet resilience during multi-year clinical programs.
Significant Treasury Asset BaseA large treasury position provides an alternative liquidity source to fund trials, opportunistic buybacks, or strategic investments without immediate equity dilution. If managed prudently, it materially lengthens runway and enables strategic optionality for pipeline advancement.
Bears Say
Persistent Operating Cash BurnConsistent negative operating and free cash flow indicate dependency on external financing or asset monetization to fund development. This structural cash burn raises dilution risk, limits discretionary spending, and pressures capital allocation while pivotal trials proceed.
No Meaningful Commercial RevenueAs a clinical-stage company with negligible revenue and persistent operating losses, Enlivex lacks internal cash generation from products. Long-term sustainability depends on trial success and external funding, making business viability contingent on clinical and regulatory outcomes.
Earnings Quality And Balance-sheet VolatilityA large 2025 earnings spike driven by unrealized treasury gains and major equity swings undermines earnings quality and introduces volatility. Reliance on mark-to-market asset appreciation complicates forecasting, creates financing unpredictability, and elevates governance and valuation risk.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $0.66 and its highest was $2.10 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $210.91M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is May 22, 2026 which is in 23 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on Mar 25, 2026. The company reported $25.79 earnings per share for the quarter, beating the consensus estimate of -$0.086 by $25.876.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate is -0.02.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 237,381,500 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of $25.79 in its last earnings report, beating expectations of -$0.086. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enlivex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (2225.58% Upside)
$20.00 (2225.58% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 11.8%
Last 30 Days ▲ 11.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.96%
12-Months-Change
Fundamentals
Return on Equity
248.08%
Trailing 12-Months
Asset Growth
8304.66%
Trailing 12-Months
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
ENLV Earnings Call
Q4 2026
0:00 / 0:00
ENLV Stock 12 Month Forecast
Average Price Target
$20.00
▲(2225.58% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.01% Mutual Funds
<0.01% Other Institutional Investors
99.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---